| First Author | Mishima E | Year | 2022 |
| Journal | Nature | Volume | 608 |
| Issue | 7924 | Pages | 778-783 |
| PubMed ID | 35922516 | Mgi Jnum | J:332780 |
| Mgi Id | MGI:7429044 | Doi | 10.1038/s41586-022-05022-3 |
| Citation | Mishima E, et al. (2022) A non-canonical vitamin K cycle is a potent ferroptosis suppressor. Nature 608(7924):778-783 |
| abstractText | Ferroptosis, a non-apoptotic form of cell death marked by iron-dependent lipid peroxidation(1), has a key role in organ injury, degenerative disease and vulnerability of therapy-resistant cancers(2). Although substantial progress has been made in understanding the molecular processes relevant to ferroptosis, additional cell-extrinsic and cell-intrinsic processes that determine cell sensitivity toward ferroptosis remain unknown. Here we show that the fully reduced forms of vitamin K-a group of naphthoquinones that includes menaquinone and phylloquinone(3)-confer a strong anti-ferroptotic function, in addition to the conventional function linked to blood clotting by acting as a cofactor for gamma-glutamyl carboxylase. Ferroptosis suppressor protein 1 (FSP1), a NAD(P)H-ubiquinone reductase and the second mainstay of ferroptosis control after glutathione peroxidase-4(4,5), was found to efficiently reduce vitamin K to its hydroquinone, a potent radical-trapping antioxidant and inhibitor of (phospho)lipid peroxidation. The FSP1-mediated reduction of vitamin K was also responsible for the antidotal effect of vitamin K against warfarin poisoning. It follows that FSP1 is the enzyme mediating warfarin-resistant vitamin K reduction in the canonical vitamin K cycle(6). The FSP1-dependent non-canonical vitamin K cycle can act to protect cells against detrimental lipid peroxidation and ferroptosis. |
